F. Liu
AstraZeneca
13 Papers
33 Citations
F. Liu is an academic researcher from AstraZeneca. The author has contributed to research in topics: Durvalumab & Tremelimumab. The author has an hindex of 7, co-authored 12 publications.
Chat about Author
Papers
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si,M. Kuziora,Katie Quinn,Elena Helman,Jiabu Ye,F. Liu,U. Scheuring,Solange Peters,Naiyer A. Rizvi,Philip Z Brohawn,Koustubh Ranade,Brandon Higgs,Kimberly C. Banks,Vikram Chand,Rajiv Raja +14 more
TL;DR: In this article, the authors used the GuardantOMNI ctDNA platform for quantifying tumor mutational burden (TMB) in the blood of patients with non-small cell lung cancer.
A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).
TL;DR: The once-weekly treatment of patients with HER2-overexpressing metastatic gastric cancer with trastuzumab + chemotherapy with or without chemotherapy is still a standard first-line option but provides only a modest overall survival.
20
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
Naiyer A. Rizvi,Byoung Chul Cho,Niels Reinmuth,Ki Hyeong Lee,Alexander Luft,Myung-Ju Ahn,Michel M. van den Heuvel,Manuel Cobo Dols,David Vicente,Alexey Smolin,Vladimir Moiseyenko,Scott J. Antonia,Kazuhiko Nakagawa,Sarah B. Goldberg,Edward S. Kim,Jill Walker,Rajiv Raja,F. Liu,U. Scheuring,Solange Peters +19 more
TL;DR: MySTIC, an open-label, Ph3 trial of first-line D (anti-PD-L1) ± T ( anti-CTLA-4) vs platinum-based CT, showed an improvement in OS with D vs CT in pts with tumor cell PD- L1 expressio...
16
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
Byoung Chul Cho,Niels Reinmuth,K.H. Lee,Myung-Ju Ahn,Alexander Luft,M. van den Heuvel,M. Cobo Dols,Alexey Smolin,David Vicente,Vladimir Moiseyenko,Scott J. Antonia,S. Le Moulec,Gilles Robinet,Ronald B. Natale,Edward B. Garon,Kazuhiko Nakagawa,F. Liu,P. Thiyagarajah,Solange Peters,Naiyer A. Rizvi +19 more
12
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.
Niels Reinmuth,Byoung Chul Cho,K.H. Lee,Alexander Luft,Myung-Ju Ahn,Jeffrey Gary Schneider,Frances A. Shepherd,Sarayut Lucien Geater,Zsolt Papai-Szekely,T. Van Ngoc,M.C. Garassino,F. Liu,Delyth Clemett,P. Thiyagarajah,Mario Ouwens,U. Scheuring,Solange Peters,Naiyer A. Rizvi +17 more
11